Cover Image

Skin lesions caused by bortezomib targeted therapy of multiple myeloma

Saved in:

Bibliographic Details
Main Authors:	Michał Sobjanek (Author), Martyna Sławińska (Author), Anna Starzyńska (Author), Małgorzata Sokołowska-Wojdyło (Author)
Format:	Book
Published:	Termedia Publishing House, 2016-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
by: Pan Zhou, et al.
Published: (2022)

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
by: Gül Kozalak, et al.
Published: (2023)

Another, new dermatosis in the spectrum of pigmented purpuric dermatoses or atypical variant of lichen aureus?
by: Martyna Sławińska, et al.
Published: (2017)

Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
by: Amany R Keruakous, et al.
Published: (2021)

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
by: Hua Wang, et al.
Published: (2018)

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma
by: Vidya Ramakrishnan, et al.
Published: (2019)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
by: Jatin J Shah, et al.
Published: (2009)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021)

ID221 Bortezomib for the treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis
by: Vania dos Santos Nunes Nogueira, et al.
Published: (2024)

Targeted therapy of multiple myeloma
by: Shan Zhou, et al.
Published: (2021)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020)

Cutaneous Drug Reaction Due to Bortezomib Characterized by Erythematous Reticular Plaques in a Patient With Multiple Myeloma
by: Emre Güven, et al.
Published: (2024)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
by: Ye Z, et al.
Published: (2019)

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
by: Muthu K. Shanmugam, et al.
Published: (2018)

Lichen spinulosus
by: Michał Sobjanek, et al.
Published: (2014)

Metastatic Multiple Myeloma to the Skin
by: Alex C. Holliday, et al.
Published: (2019)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
by: Tibullo eDaniele, et al.
Published: (2015)

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis
by: Omar S. Al-Odat, et al.
Published: (2024)

A Case of Unilateral Inflamed Plaques With Comedones on the Face: Another Case of an Uncommon Clinical Presentation of Favre-Racouchot Disease
by: Michał Sobjanek, et al.
Published: (2019)

Pigmented fungiform papillae of the tongue
by: Aleksandra Radomska, et al.
Published: (2021)

Complete remission of scleredema adultorum of Buschke associated with multiple myeloma after bortezomib-based treatment and autologous peripheral blood stem cell transplantation
by: Hsing-Jou Su, et al.
Published: (2021)

Foreign body cutaneous granuloma associated with a rose thorn: dermoscopy will tell you more
by: Anna Płaszczyńska, et al.
Published: (2022)

"Punched out" multiple myeloma lytic lesions in the skull
by: Vanessa Munhoz Bitelman, et al.
Published: (2016)

Quiz dermatologiczny
by: Martyna Kłossowska, et al.
Published: (2024)

Three distinct cutaneous malignancies arising in a post-burn scar
by: Robert Burdach, et al.
Published: (2019)

Dermoscopic features of leukemia cutis-Case series
by: M Slawinska, et al.
Published: (2021)

Multiple myeloma and kidney disease
by: Natalia Zarankiewicz, et al.
Published: (2022)

Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib
by: Saeideh Allahyari, et al.
Published: (2020)

Comment: Subcutaneous Panniculitis- like T-Cell Lymphoma: Report of two cases
by: Małgorzata Sokołowska-Wojdyło
Published: (2014)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar D, et al.
Published: (2015)

The recurrent nevus phenomenon: case series
by: Beata Zagórska, et al.
Published: (2022)

Targetoid hemosiderotic hemangioma: one tumor, different clinical presentations
by: Magdalena Badziąg, et al.
Published: (2022)